Anita C. Hohenstein, Joylynn Gallegos, Mylinh Dang, Jason Groegler, Hali Broncucia, Fatima Tensun, Kathleen Waugh, Fran Dong, Eddie A. James, Cate Speake, Andrea K. Steck, Marian J. Rewers, Peter A. Gottlieb, Kathryn Haskins, Thomas Delong, Rocky L. Baker
{"title":"Novel T Cell reactivities to Hybrid Insulin Peptides in Islet Autoantibody-Positive At-Risk Subjects","authors":"Anita C. Hohenstein, Joylynn Gallegos, Mylinh Dang, Jason Groegler, Hali Broncucia, Fatima Tensun, Kathleen Waugh, Fran Dong, Eddie A. James, Cate Speake, Andrea K. Steck, Marian J. Rewers, Peter A. Gottlieb, Kathryn Haskins, Thomas Delong, Rocky L. Baker","doi":"10.2337/db24-0611","DOIUrl":null,"url":null,"abstract":"Type 1 Diabetes (T1D) is an autoimmune disease mediated by autoreactive T cells. Our studies indicate that CD4 T cells reactive to Hybrid Insulin Peptides (HIPs) play a critical role in T cell-mediated beta-cell destruction. We have shown that HIPs form in human islets between fragments of the C-peptide and cleavage products of secretory granule proteins. To identify T cell specificities contributing to T1D pathogenesis, we tested T cell reactivity from T1D patients or healthy control using an IFN-γ ELISPOT assay against a library of 240 C-peptide HIPs. We observed elevated T cell responses to peptide pools containing HIPs that form at the amino acid residues G15, A18 and L26 of C-peptide. In a second cohort of healthy controls, at-risk individuals, and T1D patients, T cell reactivity to HIPs forming at these three residues was monitored. Results indicate that, prior to clinical onset of T1D, there were significantly elevated responses to multiple pools of HIPs, and the magnitude of T cell reactivity to HIPs forming at residue A18 of the C-peptide was increased. Overall, our study identifies new T cell specificities in at-risk subjects and indicates that T cell reactivity to HIPs can be observed before T1D onset.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"12 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-0611","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Type 1 Diabetes (T1D) is an autoimmune disease mediated by autoreactive T cells. Our studies indicate that CD4 T cells reactive to Hybrid Insulin Peptides (HIPs) play a critical role in T cell-mediated beta-cell destruction. We have shown that HIPs form in human islets between fragments of the C-peptide and cleavage products of secretory granule proteins. To identify T cell specificities contributing to T1D pathogenesis, we tested T cell reactivity from T1D patients or healthy control using an IFN-γ ELISPOT assay against a library of 240 C-peptide HIPs. We observed elevated T cell responses to peptide pools containing HIPs that form at the amino acid residues G15, A18 and L26 of C-peptide. In a second cohort of healthy controls, at-risk individuals, and T1D patients, T cell reactivity to HIPs forming at these three residues was monitored. Results indicate that, prior to clinical onset of T1D, there were significantly elevated responses to multiple pools of HIPs, and the magnitude of T cell reactivity to HIPs forming at residue A18 of the C-peptide was increased. Overall, our study identifies new T cell specificities in at-risk subjects and indicates that T cell reactivity to HIPs can be observed before T1D onset.
期刊介绍:
Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes.
However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.